Higher-dose pneumococcal vaccines improve immune response in ANCA-associated vasculitis patients receiving rituximab

Glass laboratory flasks on light table

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Airbnb will finally show you the *actual* total price in search

Previous article

In-House Vs. Outsource Blockchain Development: Which to Prefer?

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations